Millions of people with rare diseases nationwide are caught up in an ongoing legal and political debate about how the U.S. supports pharmaceutical companies and their research.
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.